UroGen Pharma (URGN) Aktienübersicht
UroGen Pharma Ltd. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung und Vermarktung von Lösungen für Urothel- und andere Krebsarten befasst. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 0/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
URGN Community Fair Values
Create NarrativeSee what 18 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
UroGen Pharma Ltd. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$42.24 |
| 52-Wochen-Hoch | US$50.81 |
| 52-Wochen-Tief | US$15.86 |
| Beta | 1.58 |
| 1 Monat Veränderung | -10.34% |
| 3 Monate Veränderung | 42.13% |
| 1 Jahr Veränderung | 119.43% |
| 3 Jahre Veränderung | 167.68% |
| 5 Jahre Veränderung | 163.34% |
| Veränderung seit IPO | 202.15% |
Aktuelle Nachrichten und Updates
Narrative-Update • Sep 10
URGN: Patent Duration And Bladder Cancer Franchise Will Guide Balanced Future Outcomes
Analysts recently raised their fair value estimate for UroGen Pharma from $40 to $48, citing higher projected profitability, a slightly lower future P/E assumption, and stronger expectations for Zusduri product sales as the main factors behind the new price target. Analyst Commentary on UroGen Pharma Recent Street research on UroGen Pharma shows a cluster of higher fair value and price targets linked closely to expectations for Zusduri.Seeking Alpha • Sep 09
Urogen Pharma: Upside After Bladder Cancer Launch
Summary UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely. I maintain a Buy rating on URGN stock, citing robust early commercial execution, significant market penetration potential, and ongoing pipeline progress, despite a short cash runway and execution risks. Read the full article on Seeking Alpha
Narrative-Update • Aug 27
URGN: Future Profit Margins Will Improve Through Bladder Cancer Pipeline Momentum
Analysts have raised the blended fair value estimate for UroGen Pharma to about $60 per share, citing expectations for higher profit margins and increased confidence in Zusduri product sales, as reflected in recent price target increases from firms including TD Cowen, Guggenheim, Oppenheimer, and Goldman Sachs. Analyst Commentary Recent research updates on UroGen Pharma focus heavily on Zusduri execution, sales trajectories, and how these flow through to valuation.Recent updates
Narrative-Update • Sep 10
URGN: Patent Duration And Bladder Cancer Franchise Will Guide Balanced Future Outcomes
Analysts recently raised their fair value estimate for UroGen Pharma from $40 to $48, citing higher projected profitability, a slightly lower future P/E assumption, and stronger expectations for Zusduri product sales as the main factors behind the new price target. Analyst Commentary on UroGen Pharma Recent Street research on UroGen Pharma shows a cluster of higher fair value and price targets linked closely to expectations for Zusduri.Seeking Alpha • Sep 09
Urogen Pharma: Upside After Bladder Cancer Launch
Summary UroGen Pharma Ltd. has transitioned into a commercial-stage biopharma, driven by strong adoption of Zusduri for recurrent non-muscle invasive bladder cancer. Zusduri achieved an 80% complete response rate in the ENVISION trial, with a 64.5% chance of remaining disease-free at 3 years among responders. URGN-103, a next-generation mitomycin-based product, is positioned to replace Zusduri, offering manufacturing and convenience advantages; NDA submission is complete and approval is likely. I maintain a Buy rating on URGN stock, citing robust early commercial execution, significant market penetration potential, and ongoing pipeline progress, despite a short cash runway and execution risks. Read the full article on Seeking AlphaNarrative-Update • Aug 27
URGN: Future Profit Margins Will Improve Through Bladder Cancer Pipeline Momentum
Analysts have raised the blended fair value estimate for UroGen Pharma to about $60 per share, citing expectations for higher profit margins and increased confidence in Zusduri product sales, as reflected in recent price target increases from firms including TD Cowen, Guggenheim, Oppenheimer, and Goldman Sachs. Analyst Commentary Recent research updates on UroGen Pharma focus heavily on Zusduri execution, sales trajectories, and how these flow through to valuation.
Narrative-Update • Aug 13
URGN: Future Bladder Cancer Franchise Durability May Reframe Long Term Upside Potential
Analysts have raised their fair value estimate for UroGen Pharma from $45.0 to $75.0, citing higher product sales expectations and stronger projected revenue growth, profit margins, and future P/E metrics. These revisions are supported by recent upward adjustments to Zusduri sales forecasts and price targets across several research firms.Analyseartikel • Aug 07
Bullish: Analysts Just Made An Incredible Upgrade To Their UroGen Pharma Ltd. (NASDAQ:URGN) Forecasts
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders will have a reason to smile today, with the analysts making substantial...Narrative-Update • Jul 30
URGN: Patent Duration And Bladder Cancer Franchise Will Shape Balanced Upside Potential
Analysts have raised the fair value estimate for UroGen Pharma to $40.00 from $32.00, citing updated sales projections for Zusduri, favorable survey feedback from prescribing urologists, and expectations for longer patent protection that could limit generic competition in non muscle invasive bladder cancer. Analyst Commentary Recent research updates on UroGen Pharma point to a mix of optimism around Zusduri and ongoing caution about execution and long term growth.Narrative-Update • Jul 16
URGN: Extended Patent Optimism Will Likely Outrun Realistic Commercial Execution
For UroGen Pharma, the analyst price target in this framework shifts from $20.55 to $32.00 as analysts factor in extended patent protection on its gel-based mitomycin franchise and early Zusduri launch progress, along with updated assumptions for revenue growth, profit margin, and future P/E. Analyst Commentary Recent Street research on UroGen Pharma highlights a mix of optimism around extended patent protection and Zusduri launch traction, alongside pockets of caution where some bearish analysts remain focused on execution risks, competition, and how much of the good news is already reflected in valuation.Narrative-Update • Jun 18
URGN: Patent Overhang And Execution Risks Will Likely Cap Stock Price Upside
Analysts have trimmed their average price target for UroGen Pharma to about $20.55, a slight adjustment they link to updated assumptions around revenue growth, profit margins and future P/E expectations. Analyst Commentary Recent Street research around UroGen Pharma highlights a mix of optimism on the product story and tighter scrutiny on what that implies for valuation, especially relative to updated assumptions on revenue, margins and future P/E multiples.Narrative-Update • Jun 04
URGN: Future Bladder Cancer Trial Milestones May Reframe Long Term Upside Potential
Analysts have reset the 12 month price target for UroGen Pharma to $45.00, reflecting updated assumptions around revenue growth, profit margins, and a slightly higher discount rate, while citing supportive recent research coverage and target increases from multiple firms. Analyst Commentary Recent research coverage on UroGen Pharma has leaned positive, with several bullish analysts updating their views and models following new information on the company and its pipeline.Narrative-Update • May 21
URGN: Future Regulatory And Funding Setbacks Will Likely Restrain Upside Potential
Narrative Update on UroGen Pharma The updated analyst price target for UroGen Pharma has shifted from about $19.68 to roughly $20.86 as analysts incorporate recent initiations and target increases, including the $5 and $6 target hikes and renewed Buy views, into their valuation work. Analyst Commentary Recent research on UroGen Pharma has leaned constructive, with several firms initiating or reaffirming Buy views and lifting their price targets.Narrative-Update • May 03
URGN: Future Regulatory And Cost Setbacks Will Likely Restrain Upside Potential
Analysts have raised their price target on UroGen Pharma from $16.57 to $19.68 as updated assumptions for revenue growth, profit margins and a lower future P/E multiple align with a recently initiated bullish view on the stock. Analyst Commentary Recent research commentary on UroGen Pharma reflects a bullish initiation that aligns with the higher price target.Narrative-Update • Apr 18
URGN: Future Profit Margins Will Improve Through LG UTUC Trial Momentum
Analysts have nudged their price target for UroGen Pharma higher to $36.11 from $35.63, reflecting updated assumptions around discount rates, revenue growth, profit margin, and future P/E following recent bullish Street research coverage. Analyst Commentary Recent Street research on UroGen Pharma has leaned constructive, which feeds into the modest uptick in the blended price target to $36.11.Narrative-Update • Apr 03
URGN: Future Profit Margins Will Improve Through New J Code Reimbursement
Analysts have modestly fine-tuned their price target framework for UroGen Pharma, keeping fair value around $35.63. Small adjustments to the discount rate, revenue growth, profit margin, and forward P/E reflect updated assumptions rather than a major change in outlook.Narrative-Update • Mar 20
URGN: Future Profit Margins Will Benefit From New J Code And Loan Refinancing
Analysts kept their fair value estimate for UroGen Pharma steady at $35.63 while making only minimal adjustments to assumptions around discount rate, revenue growth, profit margin, and future P/E. These changes reflect updated views on operating costs and financing conditions, similar to those that recently led to modest target reductions in other healthcare names.Narrative-Update • Mar 05
URGN: Future Profit Margins Will Benefit From New J Code Reimbursement
Analysts now place UroGen Pharma's fair value at about $35.63, compared with the prior $35.25. This reflects updated assumptions around a slightly higher discount rate, modestly adjusted revenue growth and profit margin expectations, and a higher future P/E estimate.Analyseartikel • Dec 05
UroGen Pharma Ltd. (NASDAQ:URGN) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders have had their patience rewarded with a 26% share price jump in the...Narrative-Update • Nov 26
URGN: Future Profit Margins Will Benefit From Recent Regulatory Milestones
Analysts have raised their price target for UroGen Pharma from $33.75 to $35.25. They cite expectations of stronger revenue growth and improved profit margins as key drivers for the increase.Analyseartikel • Oct 06
UroGen Pharma Ltd.'s (NASDAQ:URGN) Price Is Out Of Tune With Revenues
It's not a stretch to say that UroGen Pharma Ltd.'s ( NASDAQ:URGN ) price-to-sales (or "P/S") ratio of 8.5x right now...Narrative-Update • Sep 09
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Driven by an improved net profit margin and a modest reduction in future P/E, analysts have raised UroGen Pharma’s consensus price target from $32.00 to $33.75. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only approved therapy for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Narrative-Update • Aug 15
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
As there is no change in the key metrics—consensus price target ($31.43), discount rate (6.85%), and future P/E (15.67x)—analyst valuation for UroGen Pharma remains steady, reflecting an unchanged fair value. What's in the News ZUSDURI (mitomycin) received FDA approval as the first and only medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), with U.S. availability expected on or around July 1, 2025.Analyseartikel • Aug 10
The UroGen Pharma Ltd. (NASDAQ:URGN) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
NasdaqGM:URGN 1 Year Share Price vs Fair Value Explore UroGen Pharma's Fair Values from the Community and select yours...Analyseartikel • Jul 07
Optimistic Investors Push UroGen Pharma Ltd. (NASDAQ:URGN) Shares Up 84% But Growth Is Lacking
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Analyseartikel • May 17
Lacklustre Performance Is Driving UroGen Pharma Ltd.'s (NASDAQ:URGN) 30% Price Drop
The UroGen Pharma Ltd. ( NASDAQ:URGN ) share price has fared very poorly over the last month, falling by a substantial...Analyseartikel • May 15
Earnings Release: Here's Why Analysts Cut Their UroGen Pharma Ltd. (NASDAQ:URGN) Price Target To US$32.63
It's shaping up to be a tough period for UroGen Pharma Ltd. ( NASDAQ:URGN ), which a week ago released some...Neues Narrative • May 07
UGN-102 Approval Will Broaden Bladder Cancer Treatment Options
Anticipated approval of UGN-102 could significantly expand UroGen Pharma's market, boosting revenues with its compelling response rates and potential pricing power.Analyseartikel • Feb 12
Improved Revenues Required Before UroGen Pharma Ltd. (NASDAQ:URGN) Shares Find Their Feet
You may think that with a price-to-sales (or "P/S") ratio of 4.8x UroGen Pharma Ltd. ( NASDAQ:URGN ) is definitely a...Seeking Alpha • Jan 31
UroGen: Upcoming PDUFA, Some Concerns Remain
Summary UroGen's Jelmyto, a gel-based mitomycin product for LG-UTUC, achieved $25.2mn in Q3 2024, marking a 20% YoY increase. Lead candidate UGN-102 shows promise in treating low-grade intermediate risk NMIBC, with significant clinical trial success and a PDUFA date set for June 13, 2025. Financially, UroGen has a market cap of $464mn and a cash runway of 8-9 quarters, despite facing patent challenges from Teva. Despite promising data and market potential, UroGen's low market cap suggests caution; a pilot investment is recommended with awareness of associated risks. Read the full article on Seeking AlphaAnalyseartikel • Nov 18
Is UroGen Pharma (NASDAQ:URGN) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Seeking Alpha • Aug 28
UroGen Pharma: There Is Some Potential Here
Summary UroGen Pharma Ltd. focuses on urothelial and specialty cancers, with Jelmyto approved for LG-UTUC and promising pipeline candidates like UGN-102 for bladder cancer. UGN-102 should garner FDA approval in the first half of 2025 and has a much bigger potential market than Jelmyto. UroGen is also advancing some next-generation candidates within its pipeline and has adequate near-term funding in place. An analysis around UroGen Pharma follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 17
UroGen: Q3 NDA Opens Hefty Revenue Opportunity
Summary ENVISION DOR data released in Q2, 2024 showed an unprecedented 82.3% Duration of Response for UGN-102. Following such positive data, it expects to make an FDA submission late in Q3, 2024, with potential for priority review. UroGen Pharma's blockbuster drug potential, liquidity, and modest market cap make it a strong buy. Read the full article on Seeking AlphaAnalyseartikel • Jun 14
UroGen Pharma Ltd.'s (NASDAQ:URGN) Share Price Boosted 35% But Its Business Prospects Need A Lift Too
UroGen Pharma Ltd. ( NASDAQ:URGN ) shareholders would be excited to see that the share price has had a great month...Aktionärsrenditen
| URGN | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | -5.9% | -5.9% | -2.2% |
| 1Y | 119.4% | 34.6% | 13.1% |
Rendite im Vergleich zur Industrie: URGN übertraf die Branche US Biotechs , die im vergangenen Jahr eine Rendite von 34.6 erzielte.
Rendite vs. Markt: URGN übertraf den Markt US, der im vergangenen Jahr eine Rendite von 13.1 erzielte.
Preisvolatilität
| URGN volatility | |
|---|---|
| URGN Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: URGN hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: URGNDie wöchentliche Volatilität (8%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2004 | 300 | Liz Barrett | www.urogen.com |
UroGen Pharma Ltd. ist ein Biotechnologieunternehmen, das sich mit der Entwicklung und Vermarktung von Lösungen für Urothel- und Spezialkrebserkrankungen befasst. Das Unternehmen bietet RTGel, eine neuartige, proprietäre, polymere, biokompatible Hydrogeltechnologie mit umgekehrter thermischer Gelierung, Mitomycin, ein generisches Medikament, das off-label als adjuvante Chemotherapie für die Behandlung von niedriggradigem NMIBC nach transurethraler Resektion des Blasentumors verwendet wird, Zusduri, eine Formulierung mit verzögerter Freisetzung von Mitomycin für die Behandlung von nicht-muskelinvasivem Blasenkrebs (NMIBC), und Jelmyto für pyelocalyceale Lösungen. Die führenden Produktkandidaten des Unternehmens sind UGN-103, eine intravesikale Lösung, die sich in Phase 3 der klinischen Prüfung befindet, und UGN-104, eine pyelocalyceale Lösung, die sich in Phase 3 der klinischen Prüfung befindet und für die Behandlung verschiedener Formen von nicht-muskelinvasivem Urothelkarzinom entwickelt wurde, darunter niedriggradiges Urothelkarzinom des oberen Trakts und niedriggradiges NMIBC mit mittlerem Risiko.
UroGen Pharma Ltd.'s Grundlagenzusammenfassung
| URGN grundlegende Statistiken | |
|---|---|
| Marktanteil | US$2.20b |
| Gewinn(TTM) | -US$97.64m |
| Umsatz(TTM) | US$188.73m |
10.9x
Kurs-Umsatz-Verhältnis-21.1x
Kurs-Gewinn-Verhältnis Ist URGN zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| URGN Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$188.73m |
| Kosten der Einnahmen | US$17.28m |
| Bruttogewinn | US$171.46m |
| Sonstige Ausgaben | US$269.09m |
| Gewinn | -US$97.64m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -2.00 |
| Bruttomarge | 90.85% |
| Nettogewinnspanne | -51.73% |
| Schulden/Eigenkapital-Verhältnis | -142.6% |
Wie hat sich URGN auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/10 14:33 |
| Aktienkurs zum Tagesende | 2026/09/10 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
UroGen Pharma Ltd. wird von 21 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Anita Dushyanth | Berenberg |
| Paul Choi | Goldman Sachs |
| Kelsey Goodwin | Guggenheim Securities, LLC |